Conformation study of 2-arylbenzimidazoles as inhibitors of Chlamydia pneumoniae growth

被引:4
作者
Siiskonen, Antti [1 ]
Keurulainen, Leena [1 ]
Salin, Olli [2 ]
Kiuru, Paula [1 ]
Pohjala, Leena [2 ]
Vuorela, Pia [2 ]
Yli-Kauhaluoma, Jari [1 ]
机构
[1] Univ Helsinki, Fac Pharm, Bioctr Viikki, Div Pharmaceut Chem, FI-00014 Helsinki, Finland
[2] Abo Akad Univ, Dept Biosci, FI-20520 Turku, Finland
基金
芬兰科学院;
关键词
Chlamydia pneumoniae; Conformational effects; Structure-activity relationship; 2-Arylbenzimidazoles; N-Phenylbenzamides; SEROLOGICAL EVIDENCE; TWAR; ASSOCIATION; INFECTION; DISEASE; DESIGN;
D O I
10.1016/j.bmcl.2012.05.023
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Chlamydia pneumoniae is a worldwide cause of various respiratory track diseases ranging from asymptomatic pharyngeal infection to severe, sometimes fatal pneumonia. We have previously identified 2-arylbenzimidazoles as highly active antichlamydial compounds. In this work the importance of conformational effects on the structure-activity relationship of these compounds was studied. To simplify calculations, properly substituted N-phenylbenzamides, or the corresponding heterocyclic compounds, and 2-arylbenzimidazoles were used as model compounds. They were energy minimized and the energy differences between certain conformations were calculated. The main finding was that the compounds which can more easily adopt a non-planar conformation show higher bioactivity. This finding can be utilized in designing new derivatives or in constructing a pharmacophore model. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4882 / 4886
页数:5
相关论文
共 14 条
[1]   Similarity based virtual screening: A tool for targeted library design [J].
Alvesalo, JKO ;
Siiskonen, A ;
Vainio, MJ ;
Tammela, PSM ;
Vuorela, PM .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) :2353-2356
[2]   Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain [J].
Gerard, Herve C. ;
Dreses-Werringloer, Ute ;
Wildt, Kristin S. ;
Deka, Srilekha ;
Oszust, Cynthia ;
Balin, Brian J. ;
Frey, William H., II ;
Bordayo, Elizabeth Z. ;
Whittum-Hudson, Judith A. ;
Hudson, Alan P. .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2006, 48 (03) :355-366
[3]  
Gieffers J, 2001, CIRCULATION, V103, P351
[4]   CHLAMYDIA-PNEUMONIAE SP-NOV FOR CHLAMYDIA SP STRAIN TWAR [J].
GRAYSTON, JT ;
KUO, CC ;
CAMPBELL, LA ;
WANG, SP .
INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1989, 39 (01) :88-90
[5]   Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease [J].
Kalayoglu, MV ;
Libby, P ;
Byrne, GI .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (21) :2724-2731
[6]   Design and Synthesis of 2-Arylbenzimidazoles and Evaluation of Their Inhibitory Effect against Chlamydia pneumoniae [J].
Keurulainen, Leena ;
Salin, Olli ;
Siiskonen, Antti ;
Kern, Jan Marco ;
Alvesalo, Joni ;
Kiuru, Paula ;
Maass, Matthias ;
Yli-Kauhaluoma, Jari ;
Vuorela, Pia .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (21) :7664-7674
[7]   CHLAMYDIA-PNEUMONIAE (TWAR) [J].
KUO, CC ;
JACKSON, LA ;
CAMPBELL, LA ;
GRAYSTON, JT .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (04) :451-&
[8]  
Laurila AL, 1997, INT J CANCER, V74, P31, DOI 10.1002/(SICI)1097-0215(19970220)74:1<31::AID-IJC6>3.0.CO
[9]  
2-1
[10]   SEROLOGICAL EVIDENCE OF AN ASSOCIATION OF A NOVEL CHLAMYDIA, TWAR, WITH CHRONIC CORONARY HEART-DISEASE AND ACUTE MYOCARDIAL-INFARCTION [J].
SAIKKU, P ;
MATTILA, K ;
NIEMINEN, MS ;
HUTTUNEN, JK ;
LEINONEN, M ;
EKMAN, MR ;
MAKELA, PH ;
VALTONEN, V .
LANCET, 1988, 2 (8618) :983-986